Investor Presentation
Novo NordiskⓇ
47
Investor presentation First six months of 2022
Semaglutide 2.0 mg s.c. and high dose oral sema hold potential to
bring patients needing treatment intensification to target
Phase 3 trial, SUSTAIN FORTE, completed and label application
Phase 3 trial with oral semaglutide 25 mg and 50 mg in T2D has
been initiated
approved in the US and the EU
Estimand
Trial product estimand
Treatment policy estimand
Semaglutide 50 mg
Once-weekly
2.0 mg
1.0 mg
2.0 mg
1.0 mg
Semaglutide 25 mg
semaglutide
HbA1c
2.2%*
1.9%
2.1%*
1.9%
reduction
Semaglutide 14 mg
Body weight
6.9*
6.0
6.4
5.6
Dose escalation
Maintenance
reduction (kg)
Primary endpoint
after 52 weeks
HbA1c < 7.0%¹
68%
58%
Efficacy: Semaglutide 2.0 mg s.c. showed superior HbA₁ reduction with more
patients reaching target¹ versus semaglutide 1.0 mg s.c.
Safety: Semaglutide 2.0 mg appeared to have a safe and well-tolerated profile
Gastrointestinal adverse events were similar for semaglutide 2.0 mg
Nausea rates around 15%
Treatment discontinuation rates below 5%
Label expansion application approved in the US and the EU
5-weeks
follow-up
68 weeks on-treatment
Objective: Trial will assess efficacy for patients in need of improved outcomes
Primary endpoint: Confirm superiority of semaglutide 25 mg and 50 mg once-
daily versus oral semaglutide 14 mg on HbA1c reduction
1 ADA recommended treatment target
*Statistically significant
S.c.: subcutaneous; Sema: Semaglutide; T2D: Type 2 diabetesView entire presentation